Pipeline Database

UB272

Amoxicillin Sodium and Sulbactam Sodium for Injection

UB272

ProductAmoxicillin Sodium and Sulbactam Sodium for Injection

Strength0.5g: 0.25g; 1.0g: 0.5g; 2.0g: 1.0g

IndicationsUpper respiratory tract infection; Otitis media; Sinusitis; Tonsillitis; Pharyngitis; Lower respiratory tract infection; Pneumonia; Bronchitis; Chronic bronchitis; Bronchiectasis; Empyema; Lung abscess; Genitourinary tract infection; Pyelonephritis; Cystitis; Urethritis; Skin and soft tissue infection; Cellulitis; Wound infection; Furuncle; Impetigo; Pustular dermatitis; Sexually transmitted disease; Gonorrhoea; Pelvic infection; Puerperal infection; Oral abscess; Meningitis; Bacterial endocarditis; Peritonitis; Osteomyelitis; Typhoid fever; Paratyphoid fever; Endocarditis prophylaxis

TherapeuticsInfectious Diseases

GMPCN - NMPA

RegistrationChina

ModalitiesSmall Molecule

Exclusive Summary

- No patent barriers worldwide; both actives are long off-patent, enabling rapid generic registration and distribution.
- Targets high-burden infections with stable inpatient demand (≈150M UTIs/year, ≈30M adult CAP/year, ≈120M pediatric pneumonia episodes/year).
- Aligned with beta-lactam/beta-lactamase inhibitor class for H. influenzae, MSSA, common TEM/SHV Enterobacterales and anaerobes; not on WHO EML, so access via national/hospital formularies.
- Competition concentrated in Asia/CIS/LatAm with limited US/EU presence; full vial range (0.75/1.5/3.0 g total) supports hospital-tailored dosing.
- Amoxicillin-based combo typically has lower COGS than ampicillin/sulbactam at the same 2:1 inhibitor ratio, allowing aggressive pricing vs class comparators.

How can we help you?

Receive insights into the latest events and regulatory updates

Sent directly to your email

Get industry insights and Unibest news here